BlackRock, Inc. 13D and 13G filings for Arcus Biosciences, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-08 5:31 pm Unchanged | 2024-09-30 | 13G | Arcus Biosciences, Inc. RCUS | BlackRock Inc. BLK | 9,732,399 10.600% | 0 (Unchanged) | Filing |
| 2024-10-23 5:04 pm Sale | 2024-09-30 | 13G | Arcus Biosciences, Inc. RCUS | BlackRock Inc. BLK | 9,732,399 10.600% | -302,771 (-3.02%) | Filing |
| 2024-01-23 11:52 am Purchase | 2023-12-31 | 13G | Arcus Biosciences, Inc. RCUS | BlackRock Inc. BLK | 10,035,170 13.400% | 646,122 (+6.88%) | Filing |
| 2023-01-26 08:43 am Unchanged | 2022-12-31 | 13G | Arcus Biosciences, Inc. RCUS | BlackRock Inc. BLK | 9,389,048 13.000% | 0 (Unchanged) | Filing |
| 2023-01-20 09:43 am Purchase | 2022-12-31 | 13G | Arcus Biosciences, Inc. RCUS | BlackRock Inc. BLK | 9,389,048 13.000% | 1,421,371 (+17.84%) | Filing |
| 2022-05-09 3:23 pm Purchase | 2022-04-30 | 13G | Arcus Biosciences, Inc. RCUS | BlackRock Inc. BLK | 7,967,677 11.100% | 3,837,748 (+92.93%) | Filing |
| 2022-02-04 4:12 pm Purchase | 2021-12-31 | 13G | Arcus Biosciences, Inc. RCUS | BlackRock Inc. BLK | 4,129,929 5.900% | 758,628 (+22.50%) | Filing |
| 2021-03-09 6:33 pm Purchase | 2021-02-28 | 13G | Arcus Biosciences, Inc. RCUS | BlackRock Inc. BLK | 3,371,301 4.800% | 116,210 (+3.57%) | Filing |
| 2021-02-02 2:56 pm Purchase | 2020-12-31 | 13G | Arcus Biosciences, Inc. RCUS | BlackRock Inc. BLK | 3,255,091 5.000% | 763,110 (+30.62%) | Filing |
| 2020-06-09 4:32 pm Sale | 2020-05-31 | 13G | Arcus Biosciences, Inc. RCUS | BlackRock Inc. BLK | 2,491,981 4.400% | -516,781 (-17.18%) | Filing |